• American Chamber of Commerce in Korea
  • Your Partner in Business Since 1953



home> >

AMCHAM Joint Legal Affairs and Pharmaceutical Committee Meeting
  ►SPEAKER Kristel Schorr
Partner & Chair, Chemical Biotechnology and Pharmaceutical Practice Foley & Lardner LLP
Stephen B. Maebius
Partner, Foley & Lardner LLP
  ►TOPIC Optimizing use of inter partes review (IPR) and ex parte reexaminations as a commercialization strategy for biologics and biosimilars in the US  
  ►DATE Thursday, March 16th, 2017  
  ►TIME 7:30am - 8:00am: Registration / Networking
8:00am - 9:30am: Breakfast / Speech/ Q&A
  ►VENUE AMCHAM Office -Yeouido Subway Station (Line 5 and 9) Exit #3
(15F, Two IFC, 10, Gukjegeumyung-ro, Yeongdeungpo-gu, Seoul)
  ►COST KRW35,000 for members
KRW55,000 for non-members
(Inclusive of breakfast. Exclusive of parking)
*Use of public transportation is encouraged as parking fee at IFC is KRW4,000/hour
  ►RSVP/PAYMENT BY Noon, Wednesday, March 15th, 2017
*No refunds or cancellations made after this date and time.
*Due to the room capacity of maximum 35 participants, we will be receiving RSVPs on a first-come-first-served basis and no walk-ins will be allowed.
  ►CONTACT (email) amchamrsvp@amchamkorea.org, (phone) 82.2.6201.2200  
      Kristel Schorr
Kristel Schorr is a partner at Foley & Lardner and chair of its Chemical, Biotechnology & Pharmaceutical Practice. Kristel counsels life sciences clients on intellectual property matters including due diligence, invalidity and non-infringement options, interferences and inter partes review proceedings in various technical areas such as immunology, oncology and molecular and cell biology.
click to view SPEAKER'S FULL BIO
      Stephen B. Maebius
Steve Maebius is a partner at Foley & Lardner, and former member of the firm’s Management Committee and past chair of the Intellectual Property Department. Steve handles a variety of IP work, including due diligence, infringement and validity opinions, licensing, litigation with parallel inter partes reviews and pharmaceutical patent term extensions.
click to view SPEAKER'S FULL BIO

Dear AMCHAM Members,

Please join the AMCHAM Legal Affairs Committee at this breakfast meeting to learn more about commercialization strategies for life sciences companies in preparation for entry of a biologic or biosimilar into the US market. Steve and Kristel will focus on the use of IPRs and ex parte reexaminations to clear patent hurdles before commercializing a biosimilar product, procedural aspects and advantages and disadvantages of each of these proceedings, the timing of initiating such proceedings, and case studies relating to successful biosimilar IPRs. This session should be useful for companies considering the most cost-effective legal strategies for facilitating early biosimilar market entry in the US, and lawyers and executives seeking to understand the cost and risks associated with patent challenges.

Best regards,

AMCHAM Legal Affairs & Pharmaceuticals Committees

Legal Affairs Co-Chairs
Anthony Chang / David Waters

Pharmaceuticals Co-Chairs
Kyungsun Kyle Choi / TS Chung / Paul Huibers / Sung-Hye Hwang

  click to view OTHER UPCOMING EVENTS  
15F, Two IFC, 10, Gukjegeumyung-ro, Yeongdeungpo-gu, Seoul 07326, Korea
Copyright © American Chamber of Commerce in Korea. All Rights Reserved.